An Enhanced Delivery Ecosystem for Neurosurgery in 2020
COVID-19 UPDATE: 03 March 2021
COVID-19 continues to impact our lives, and our work in many ways. EDEN2020 clinical studies are still postponed until such time as it is deemed safe for EDEN2020 clinicians and researchers to return. With the vaccine roll-out, this seems to be on the horizon. Our funding body, the European Commission has supported our risk mitigation efforts and have granted the consortium a 6-month grace period in which to deliver the final clinical validation work. The EDEN2020 consortium are now closely monitoring the European COVID-19 response and action and developing their strategies for the recommencement of EDEN2020 clinical work.
We thank the European Commission and our consortium for the continued support during these unprecedented times.
For further information, the European Commission has placed up-to-date information on their website regarding COVID-19 response and action.
Prof Ferdinando Rodriguez y Baena
Imperial College London
EDEN2020 coordinator and on behalf of the EDEN2020 consortium
Due to an ageing population and the spiralling cost of brain disease in Europe and beyond, EDEN2020 aims to develop the gold standard for one-stop diagnosis and minimally invasive treatment in neurosurgery. Supported by a clear business case, it will exploit the unique track record of leading research institutions and key industrial players in the field of surgical robotics to overcome the current technological barriers that stand in the way of real clinical impact.
EDEN2020 will provide a step change in the modelling, planning and delivery of diagnostic sensors and therapies to the brain via flexible surgical access, with an initial focus on cancer therapy. It will engineer a family of steerable catheters for chronic disease management that can be robotically deployed and kept in situ for extended periods. The system will feature enhanced autonomy, surgeon cooperation, targeting proficiency and fault tolerance with a suite of technologies that are commensurate to the unique challenges of neurosurgery. Amongst these, the system will be able to sense and perceive intraoperative, continuously deforming, brain anatomy at unmatched accuracy, precision and update rates, and deploy a range of diagnostic optical sensors with the potential to revolutionise today’s approach to brain disease management. By modelling and predicting drug diffusion within the brain with unprecedented fidelity, EDEN2020 will contribute to the wider clinical challenge of extending and enhancing the quality of life of cancer patients – with the ability to plan therapies around delicate tissue structures and with unparalleled delivery accuracy.
EDEN2020 is strengthened by a significant industrial presence, which is embedded within the entire R&D process to enforce best practices and maximise translation and the exploitation of project outputs. As it aspires to impact the state of the art and consolidate the position of European industrial robotics, it will directly support the Europe 2020 Strategy.